Market open
$
36.07
Change
+0.18 +0.50%
Volume
Volume 1.14m
Oct 4, 2023, 11:37 a.m.
Real time quotes
Previous close
$ 35.89
$ 36.07
Change
+0.18 +0.50%
Day low
Day high
$35.84
$36.25

52 week low
52 week high
$29.76
$39.74

Market cap
$73.03B
Average volume
3.51M
P/E ratio
4.15
Rev. per Employee
$508,459
EPS
8.67
Dividend
0.36
Div yield
3.80%
Ex dividend date
8/17/23
MarketWatch News on GSK
-
Moderna Says Flu-Covid Vaccine Succeeds in Early-Stage Trial
- Barron's Online
-
The Bond and Stock Selloff Has Momentum. Here’s How It Could End.
- Barron's Online
-
Novartis Spinoff of Generic Drug Division Starts Today
- Barron's Online
-
Moderna aims to prove it’s ‘more than a COVID company’
- Eleanor Laise
-
CureVac signals progress on mRNA flu vaccine
- Eleanor Laise
-
Biden Administration to Reveal 10 Drugs for Which Medicare Will Pay Less
- Barron's Online
-
Pfizer maternal RSV vaccine gets FDA approval
- Eleanor Laise
-
Tylenol Litigation Could Be a Headache for Kenvue
- Barron's Online
-
J&J's $40 Billion Kenvue Stock Swap: What to Know
- Barron's Online
-
CDC Recommends New Sanofi, AstraZeneca Shot to Prevent RSV in Babies
- Barron's Online
-
Moderna Vaccine Forecast Raises Hope, Worry
- Barron's Online
-
Pfizer Cuts Guidance in Face of 'Near-Term' Setbacks
- Barron's Online
-
Vir Biotechnology Stock Plunges on Flu Trial Failure
- Barron's Online
-
5 Beaten-Down Healthcare Stocks With Potential for a Rebound
- Barron's Online
-
40 Investment Ideas From Our Roundtable Pros
- Barron's Online
-
Shake Shack Stock Blows Through the Roof. 23andMe Tumbles.
- Barron's Online
- Loading more headlines...
Analyst Ratings
-
Johnson & Johnson: Analyst Recommendations and Target Price
- MarketRealist.com
-
Analysts See a 9.5% Upside for SNY Stock over the Next Year
- MarketRealist.com
-
Analysts’ Recommendations for Valeant in June
- MarketRealist.com
Other News on GSK
-
New Covid-19 Vaccines and More Free Mail-Order Tests. What to Know for This Fall.
- The Wall Street Journal Interactive Edition
-
FDA Approves RSV Vaccine to Pass Protection From Mother to Child
- The Wall Street Journal Interactive Edition
-
Johnson & Johnson Rips Off the Kenvue Band-Aid
- The Wall Street Journal Interactive Edition
-
Next Vaccine You Should Get? U.S. Health Advisers Back RSV Shots
- The Wall Street Journal Interactive Edition
-
New Pfizer RSV Vaccine Rolls Out Into Headwinds of Hesitancy
- The Wall Street Journal Interactive Edition
-
Gucci-Owner Kering, Drugmaker GSK and Others Are Developing Global Targets on Nature Loss
- The Wall Street Journal Interactive Edition
-
FDA Approves GSK’s RSV Vaccine for Older Adults
- The Wall Street Journal Interactive Edition
-
Europe’s Threat to Drug Patents
- The Wall Street Journal Interactive Edition
-
Regeneron, Sanofi Look for Billions From COPD Drug
- The Wall Street Journal Interactive Edition
-
Chinese Authorities Raid Office of U.S. Investigations Firm Mintz
- The Wall Street Journal Interactive Edition
-
Biologists Say Deep Learning Is Revolutionizing Pace of Innovation
- The Wall Street Journal Interactive Edition
-
Bernie Sanders Holds a Moderna Show Trial
- The Wall Street Journal Interactive Edition
-
Johnson & Johnson: Creating Shareholder Value
- GuruFocus.com
-
Moderna Peers Over a Scary Profit Cliff
- The Wall Street Journal Interactive Edition
-
Top 5 4th Quarter Trades of CITIZENS & NORTHERN CORP
- GuruFocus.com
-
Top 5 4th Quarter Trades of HealthInvest Partners AB
- GuruFocus.com
-
Kahn Brothers Buys 1, Sells 4 in 4th Quarter
- GuruFocus.com
-
Top 5 4th Quarter Trades of BUCKHEAD CAPITAL MANAGEMENT LLC
- GuruFocus.com
-
WELCH & FORBES LLC Buys 3, Sells 2 in 4th Quarter
- GuruFocus.com
- Loading more headlines...
Press Releases on GSK
-
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
- BusinessWire - BZX
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com